|
CONSIDERATIONS FOR:
FLEXIBLE CONTAINMENT OF POTENT COMPOUNDS
Capital and Operating Costs, Time, Efficacy
January 20, 2010 WEBINAR
NOON - 1:30 pm EST
This webinar will guide you through the quality, health and safety, and environmental expectations and operating costs resulting from the use of flexible enclosures for handling potent compounds.
In this webinar you will:
- Review a case study where adoption of flexible containment resulted in 4% savings ($6 million) against capital budget
- Understand comparisons of efficacy of flexible versus rigid containment
- See first time costs for both
- Examine the surface finishes present in a manufacturing rigid enclosure and how that impacts cleaning costs
- Review a comparison of utilities for flexible versus rigid containment
- Compare commissioning cost of flexible versus rigid containment
- Compare the cost of operator training for both flexible and rigid containment
- Analyze operating costs of flexible versus rigid containment
- Learn the rationale for the use of flexible containment
- Examine design considerations based on attributes & weaknesses of flexible barriers
- Review a case study of an in-process sampler
- Identify potential users of flexible containment
- Identify extended uses for flexible enclosures
- Observe next evolutionary step for flexible barriers
FEE: $365 for one person.
Call for special per person discounts for multiple participants from your company.
I nstructor: Brian Ward, Ph.D, CChem, CSci, CIH, FRSC
Brian Ward has over 40 years experience in dealing with hazardous materials and is recognized by his peers as the “father” of flexible containment. He is grounded in working with: radioactive materials purification, thermal degradation, and activation analysis.
Dr. Ward has developed innovative, disposable, and cost effective containment solutions for bench scale, pilot plant, and full scale operations based on prior experience and involvement with asbestos abatement practices. His most recent experiences were enabling high potency API manufacture in an open facility, and retrofit of walk-in lab. hoods for contained syntheses of potent drug trial materials.
In addition, Dr. Ward had developed statistically valid test protocols beyond the SMEPAC/ISPE Guideline to measure engineering performance of containment approaches with documentation of robust isolation factors and extended these protocols to include full facility capability.
610-399-4897
ECCWEB 152
|
|
